Strs Ohio Sells 600 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Strs Ohio lessened its holdings in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTAGet Rating) by 4.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,300 shares of the biotechnology company’s stock after selling 600 shares during the quarter. Strs Ohio’s holdings in Enanta Pharmaceuticals were worth $741,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Martingale Asset Management L P increased its stake in Enanta Pharmaceuticals by 1.9% during the 2nd quarter. Martingale Asset Management L P now owns 15,706 shares of the biotechnology company’s stock valued at $743,000 after purchasing an additional 300 shares in the last quarter. Arizona State Retirement System increased its stake in Enanta Pharmaceuticals by 6.9% during the 2nd quarter. Arizona State Retirement System now owns 5,285 shares of the biotechnology company’s stock valued at $250,000 after purchasing an additional 340 shares in the last quarter. Texas Permanent School Fund increased its stake in Enanta Pharmaceuticals by 3.0% during the 2nd quarter. Texas Permanent School Fund now owns 13,324 shares of the biotechnology company’s stock valued at $630,000 after purchasing an additional 385 shares in the last quarter. Virtus ETF Advisers LLC increased its stake in Enanta Pharmaceuticals by 8.3% during the 2nd quarter. Virtus ETF Advisers LLC now owns 5,798 shares of the biotechnology company’s stock valued at $274,000 after purchasing an additional 445 shares in the last quarter. Finally, Yousif Capital Management LLC increased its stake in Enanta Pharmaceuticals by 2.8% during the 1st quarter. Yousif Capital Management LLC now owns 16,477 shares of the biotechnology company’s stock valued at $1,173,000 after purchasing an additional 445 shares in the last quarter. Institutional investors own 93.68% of the company’s stock.

Wall Street Analyst Weigh In

ENTA has been the subject of several recent analyst reports. Royal Bank of Canada reduced their target price on shares of Enanta Pharmaceuticals from $65.00 to $54.00 and set a “sector perform” rating for the company in a research note on Tuesday, November 22nd. StockNews.com initiated coverage on shares of Enanta Pharmaceuticals in a research note on Wednesday, October 12th. They issued a “hold” rating for the company. JMP Securities reiterated a “buy” rating and issued a $96.00 target price on shares of Enanta Pharmaceuticals in a research note on Tuesday, November 22nd. Oppenheimer set a $50.00 target price on shares of Enanta Pharmaceuticals in a research note on Thursday, November 24th. Finally, HC Wainwright initiated coverage on shares of Enanta Pharmaceuticals in a research note on Friday, December 9th. They issued a “buy” rating and a $56.00 target price for the company. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $66.00.

Insider Buying and Selling at Enanta Pharmaceuticals

In other Enanta Pharmaceuticals news, CEO Jay R. Luly sold 30,000 shares of the company’s stock in a transaction dated Friday, December 16th. The shares were sold at an average price of $44.72, for a total transaction of $1,341,600.00. Following the sale, the chief executive officer now directly owns 773,805 shares of the company’s stock, valued at $34,604,559.60. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 12.42% of the company’s stock.

Enanta Pharmaceuticals Stock Performance

Shares of NASDAQ:ENTA opened at $51.46 on Tuesday. The company’s 50-day moving average is $45.52 and its 200 day moving average is $51.78. The company has a market capitalization of $1.07 billion, a P/E ratio of -8.71 and a beta of 0.48. Enanta Pharmaceuticals, Inc. has a fifty-two week low of $37.59 and a fifty-two week high of $79.50.

Enanta Pharmaceuticals (NASDAQ:ENTAGet Rating) last released its quarterly earnings data on Monday, November 21st. The biotechnology company reported ($1.27) EPS for the quarter, beating the consensus estimate of ($1.37) by $0.10. The business had revenue of $20.32 million for the quarter, compared to the consensus estimate of $22.86 million. Enanta Pharmaceuticals had a negative net margin of 141.31% and a negative return on equity of 34.73%. The company’s revenue was down 13.8% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.22) earnings per share. As a group, research analysts predict that Enanta Pharmaceuticals, Inc. will post -4.05 earnings per share for the current year.

Enanta Pharmaceuticals Profile

(Get Rating)

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.

Recommended Stories

Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTAGet Rating).

Institutional Ownership by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.